Adaptimmune Therapeutics plc
Climate Impact & Sustainability Data (2022, 2023, 2024-01 to 2024-03, 2024-01 to 2024-09, 2024-03)
Reporting Period: 2022
Environmental Metrics
Social Achievements
- Established a Diversity and Inclusion Council and plan, with progress updates reviewed by the Board Remuneration Committee.
- Headcount reduction of approximately 25% completed in Q1 2023.
Climate Goals & Targets
Environmental Challenges
- Supply chain disruptions due to the COVID-19 pandemic and prioritization of vaccine supplies.
- Heightened economic uncertainty and capital markets volatility impacting fundraising.
- Material weakness related to risk assessment process over deferred income taxes identified in 2021.
Mitigation Strategies
- Purchasing materials in advance, prioritizing supply use, and sourcing alternative suppliers.
- Headcount reduction and de-prioritization of non-core programs to extend cash runway.
- Implemented new procedures and controls, increased internal skills and knowledge to remediate material weakness.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2023
Environmental Metrics
Social Achievements
- Established a Diversity and Inclusion Council and plan, with progress updates reviewed by the Board Remuneration Committee.
- Employs individuals from approximately 26 different nationalities.
Climate Goals & Targets
Medium-term Goals:
- BLA filing for lete-cel in 2026.
Short-term Goals:
- Commercial launch of afami-cel in the third quarter of 2024.
Environmental Challenges
- Global economic uncertainty, including inflation and supply chain disruptions due to the Russian/Ukrainian and Israel/Hamas conflicts.
- Intense competition in the biopharmaceutical industry.
- Complex and highly regulated manufacturing process for cell therapies.
- Reliance on third-party manufacturers and suppliers.
- Regulatory hurdles and uncertainties in obtaining marketing approvals.
- Potential product liability claims.
- Challenges in attracting and retaining qualified personnel.
- Cybersecurity risks.
- Volatility in the market price of ADSs.
- Difficulty in enforcing civil liabilities against the company due to its incorporation in England and Wales.
Mitigation Strategies
- Monitoring adverse impacts on the global economy and supply chains.
- Building internal marketing and sales capabilities and establishing relationships with third-party collaborators.
- Implementing robust quality control and quality assurance measures.
- Diversifying supplier base where possible.
- Proactively engaging with regulatory authorities.
- Maintaining adequate product liability insurance.
- Implementing competitive compensation and benefits packages.
- Investing in cybersecurity tools and processes.
- Maintaining compliance with Nasdaq listing requirements.
- Establishing an EU subsidiary to comply with EU regulations.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2024-01 to 2024-03
Environmental Metrics
Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed
ESG Focus Areas
- Not disclosed
Environmental Achievements
- Not disclosed
Social Achievements
- Not disclosed
Governance Achievements
- Not disclosed
Climate Goals & Targets
Long-term Goals:
- Not disclosed
Medium-term Goals:
- Not disclosed
Short-term Goals:
- Not disclosed
Environmental Challenges
- Not disclosed
Mitigation Strategies
- Not disclosed
Supply Chain Management
Supplier Audits: Not disclosed
Responsible Procurement
- Not disclosed
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: Null
Certifications: Null
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Not disclosed
Reporting Period: 2024-01 to 2024-09
Environmental Metrics
Climate Goals & Targets
Medium-term Goals:
- Have a full network of approximately 30 ATCs active by the end of 2025.
Short-term Goals:
- Complete the majority of the 33% workforce reduction by the end of the first quarter of 2025.
Environmental Challenges
- Maintaining compliance with Nasdaq listing requirements due to share price falling below $1.00 for 30 consecutive business days.
- Securing additional capital to fund operations.
- Successfully commercializing Tecelra in the US.
- Complexities in manufacturing and supplying cell therapies.
- Potential for delayed adverse events following gene therapy.
- Regulatory scrutiny and potential changes in government regulations.
Mitigation Strategies
- Monitoring share price and assessing actions to regain compliance with Nasdaq requirements.
- Planning a 33% reduction in workforce to reduce expenses.
- Activating authorized treatment centers for Tecelra.
- Recruiting experienced commercial and medical affairs teams.
- Developing further assays and modifying protocols to improve safety and effectiveness.
- Conducting surveillance to monitor the safety and efficacy of Tecelra.